Selinexor added to temozolomide for recurring brain glioblastoma
Treatments studied
Part of Cancer clinical trials.
This trial studies whether adding selinexor to the standard chemotherapy temozolomide (with radiation) can better treat glioblastoma that has come back after prior treatment. If you meet specific tumor, health, and lab requirements, the goal is to slow tumor growth or improve symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have confirmed glioblastoma that is IDH-wildtype and MGMT promoter methylated, and it has come back after surgery/biopsy.
- Before your surgery/biopsy for the recurrence, there must have been measurable tumor on MRI (at least one clear enhancing spot about 10 mm or larger).
- Your first treatment must have been temozolomide plus radiation, and for this recurrence you must not have had any other anti-cancer therapy yet (besides surgery/biopsy).
- You must be 18 or older and able to do daily activities fairly well (Karnofsky score at least 60, or ECOG 0–2).
- Your blood counts and organ function must meet minimum lab thresholds (for example, neutrophils, platelets, hemoglobin, and liver/kidney tests within limits).
- You must be willing and able to use reliable birth control (or agree to no pregnancy) during the study and for a period after, and you cannot be pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called selinexor (KPT-330) combined with various standard treatments for patients whose multiple myeloma has come back or stopped responding to therapy. The goal is to see if adding selinexor helps control the cancer better than current options, and to find the safest dose for different drug pairings.
This trial tests a new combination of drugs (selinexor, temozolomide, and an immunotherapy) for people whose primary central nervous system lymphoma has come back or stopped responding to previous treatment. The goal is to see if this combination can help shrink or control the lymphoma.
This study tests a combination of two oral medications, niraparib and temozolomide, for people whose brain tumor (glioblastoma or a related glioma) has come back after standard treatment. The goal is to see if this combination can slow or stop the tumor from growing.
This trial tests a combination of two drugs—ivoximab (a new immunotherapy) and temozolomide (chemotherapy)—to treat gliomas (brain tumors) that have come back or stopped responding to prior treatment. The goal is to see if this combination is safe and effective.
This trial tests a new drug, selinexor, combined with standard ICE chemotherapy for patients whose B-cell non-Hodgkin lymphoma has spread to the brain or spinal cord. It aims to see if adding selinexor improves treatment results.
This trial tests a combination of two drugs, bortezomib and temozolomide, for people whose brain tumor (glioblastoma) has returned after initial treatment. It's designed for tumors that don't respond well to standard treatments, and the goal is to see if this combination can help control the cancer.
Hear when a new Recurrent Glioblastoma, IDH-Wildtype trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.